论文部分内容阅读
目的评价甘精胰岛素治疗新诊断T2DM患者的降糖效果及对胰腺功能的影响。方法新诊断T2DM患者50例,随机分为治疗组(甘精胰岛素联合二甲双胍、阿卡波糖)和对照组(格列美脲联合二甲双胍、阿卡波糖),治疗12周。结果治疗后两组HbA1c、FBG、2hBG较治疗前显著下降(P<0.01);治疗组FC-P及2hC-P显著高于对照组(P<0.05),低血糖发生次数显著低于对照组(P<0.05)。结论甘精胰岛素联合口服药物能够有效降低血糖、促进胰岛β细胞功能恢复、低血糖发生少,为新诊断T2DM患者行之有效的降糖方案。
Objective To evaluate the effect of insulin glargine in the treatment of newly diagnosed T2DM patients on hypoglycemic effect and its effect on pancreatic function. Methods Fifty newly diagnosed T2DM patients were randomly divided into treatment group (glargine plus metformin and acarbose) and control group (glimepiride combined with metformin and acarbose) for 12 weeks. Results The levels of HbA1c, FBG and 2hBG in the two groups were significantly decreased after treatment (P <0.01); the levels of FC-P and 2hC-P in the treatment group were significantly higher than those in the control group (P <0.05); the incidence of hypoglycemia was significantly lower than that in the control group (P <0.05). Conclusion Glargine combined with oral drugs can effectively reduce blood glucose and promote the recovery of pancreatic β-cell function, with less hypoglycemia, which is an effective hypoglycemic regimen for newly diagnosed T2DM patients.